| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -51.2 | -54.9 |
| EPS (diluted, $ a share) | $-0.25 | $-0.37 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ANNX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Annexon, Inc.: key numbers
- Share price
- $3.57Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Annexon, Inc.
All →Annexon Financial Results
Annexon reported Q3 2026 financial results, highlighting a cash position of $213 million providing a runway into 2028. The company is preparing for a U.S. BLA submission for tanruprubart in GBS in Q4 2026 and expects a primary endpoint readout for its Phase 3 ARCHER II trial in geographic atrophy in Q4 2026.
- Term
- Q3 2026
“Annexon is well-positioned for a transformative next 12 months, with multiple value-creating milestones expected across our differentiated upstream C1q platform. By targeting C1q tanruprubart and vonaprument have each demonstrated first-in-kind benefits in clinical trials to date, with tanruprubart accelerating functional recovery in Guillain-Barré syndrome (GBS) and vonaprument protecting vision in geographic atrophy (GA).”
Douglas Love, President and Chief Executive Officer of Annexon